Elucidating the influence of praziquantel nanosuspensions on the in vivo metabolism of Taenia crassiceps cysticerci

Silva, Luciana Damacena; Arrúa, Eva Carolina; Pereira, Dayanne Amaral; Fraga, Carolina Miguel; Costa, Tatiane Luiza da; Hemphill, Andrew; Salomón, Claudio J.; Vinaud, Marina Clare

doi:10.1016/j.actatropica.2016.06.002

Cited by 24 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the bibliography, nanoprecipitation is one of the most suitable techniques to prepare solid colloidal particles in the range of nanometer [57]. In this study, the selection of the polymers and stabilizer, the stirring speed and the freeze-drying process confirmed the robustness of the methodology to obtain NP in high yield [34,39]. On the other hand, spray-drying process exhibit several advantages over other solvent evaporation procedures, as already described.…”

Section: Yield Loading Capacity and Entrapment Efficiencysupporting

confidence: 86%

Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?

Seremeta

Arrúa

Okulik

et al. 2019

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

Section: Yield Loading Capacity and Entrapment Efficiencysupporting

confidence: 86%

Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?

Seremeta

Arrúa

Okulik

et al. 2019

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

“…With respect to other parasitic infections, SLN formulations have shown promising findings over conventional PZQ in cestodal infection with the use of a low dose (5 mg/kg) in dogs infected with Echinococcus granulosus [54]. Additionally, using nanoprecipitation, a PZQ nanosuspension showed better efficacy against the cysticerci of the cestode parasite Taenia crassiceps [20]. In the present study, the enhanced bioavailability of PZQ in the SLN delivery system was recorded in addition to higher efficacy in mice infected with S. mansoni and treated with this formulation.…”

Section: Discussionmentioning

confidence: 99%

“…PZQ in nanoformulation may overcome its known drawbacks (quick first pass metabolism in the liver) with its consequent reduced efficacy, specifically against the immature forms in the systemic circulation. Several promising drug delivery systems were examined for PZQ [17–20]. Incorporating drugs into nanocarriers, specifically “solid lipid nanoparticles (SLNs)”, has a superior advantage over common nanoformulations with respect to drug targeting, release, long-shelf stability, low toxicity, better bioavailability and compatibility with several routes of administration [21, 22].…”

Section: Introductionmentioning

confidence: 99%

A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

et al. 2019

View full text Add to dashboard Cite

Background Schistosomiasis is responsible for a considerable global disease burden. This work aimed to improve the therapeutic outcome of the only available antischistosomal drug worldwide, praziquantel (PZQ), by incorporating it into a novel carrier, “solid lipid nanoparticles (SLNs)”, to enhance its solubility, bioavailability and efficacy. A simple, cost-effective method was used to prepare SLN-PZQ. Results Compared to market PZQ (M-PZQ), SLN-PZQ was more bioavailable, as denoted by higher serum concentrations in both normal and infected mice where elevated K a , AUC 0–24 , C max , and t 1/2e with a decrease in k el were demonstrated. The AUC 0–24 for SLN-PZQ in normal and Schistosoma mansoni -infected groups was almost nine- and eight-fold higher, respectively, than that for M-PZQ in corresponding groups. In normal and S. mansoni -infected mice, SLN-PZQ was detectable in serum at 24 h, while M-PZQ completely vanished 8 h post-treatment. Additionally, enhanced absorption with extended residence time was recorded for SLN-PZQ. Compared to M-PZQ, SLN-PZQ revealed superior antischistosomal activity coupled with enhanced bioavailability in all treated groups where higher percentages of worm reduction were recorded with all dosages tested. This effect was especially evident at the lower dose levels. The ED 95 of SLN-PZQ was 5.29-fold lower than that of M-PZQ, with a significantly higher reduction in both the hepatic and intestinal tissue egg loads of all treated groups and almost complete disappearance of immature deposited eggs (clearly evident at the low dose levels). Conclusions SLN-PZQ demonstrated enhanced PZQ bioavailability and antischistosomal efficacy with a safe profile despite the prolonged residence in the systemic circulation.

show abstract

“…In addition, most parasites, e.g. Leishmania amphotericin B, reside in intracellular, which leads to poor therapeutic effects due to the weak transmembrane and intracellular transfer ability of antiparasitic drugs (Silva et al., 2016). It is also reported that the resistances of antiparasitic drugs are becoming more and more serious due to the vast and irrational usages.…”

Section: Problems Of Antiparasitic Drugs In the Treatment Of Parasitimentioning

confidence: 99%

“…ivermectin liposomes constituents (soy lecithin and cholesterol) (Velebný et al., 2000), phospholipids in albendazole liposomes (Wen et al., 1996), phosphatidyliner in praziquantel liposomes (Zhang et al., 2000) and mannitol (Rathore et al., 2011) in amphotericin liposomes. These constituents can be biodegraded in vivo without producing any toxic substances, and simultaneously reduce the side effects of drugs (Balaña-Fouce et al., 1998; She et al., 2010; Rathore et al., 2011; Silva et al., 2016).…”

Section: Enhanced Therapy Effects Of Antiparasitic Drugs By Nanopartimentioning

confidence: 99%

Nanoparticles for antiparasitic drug delivery

Sun¹,

Chen

Pan³

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

As an emerging novel drug carrier, nanoparticles provide a promising way for effective treatment of parasitic diseases by overcoming the shortcomings of low bioavailability, poor cellular permeability, nonspecific distribution and rapid elimination of antiparasitic drugs from the body. In recent years, some kinds of ideal nanocarriers have been developed for antiparasitic drug delivery. In this review, the progress of the enhanced antiparasitic effects of different nanoparticles payload and their influencing factors were firstly summarized. Secondly, the transport and disposition process in the body were reviewed. Finally, the challenges and prospects of nanoparticles for antiparasitic drug delivery were proposed. This review will help scholars to understand the development trend of nanoparticles in the treatment of parasitic diseases and explore strategies in the development of more efficient nanocarriers to overcome the difficulty in the treatment of parasite infections in the future.

show abstract

Elucidating the influence of praziquantel nanosuspensions on the in vivo metabolism of Taenia crassiceps cysticerci

Cited by 24 publications

References 29 publications

Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?

Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?

A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

Nanoparticles for antiparasitic drug delivery

Contact Info

Product

Resources

About